Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase Ⅲ Clinical Trial on the Efficacy and Safety of Felbinac Trometamol Injection in the Treatment of Moderate and Severe Postoperative Pain

NCT04526132 is registered in ClinicalTrials.gov with Shijiazhuang Yiling Pharmaceutical Co. Ltd as lead sponsor.

NCT NCT04526132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04526132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase Ⅲ Clinical Trial on the Efficacy and Safety of Felbinac Trometamol Injection in the Treatment of Moderate and Severe Postoperative Pain
Lead sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase
Phase 3
Overall status
Completed
Start date
April 25, 2021
Completion date
June 30, 2022
Enrollment
306 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pain